Eckert & Ziegler stock trades 1.11 percent below its prior close before results

Published on 10/05/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached EUR 149.30 million, up 0.34 percent year on year. Eckert & Ziegler stock costs EUR 12.46 on October 5, 2026 after EUR 12.60.

Bauhaus-Designposter mit geometrischen Formen, Primärfarben und MEDTECH-Schriftzug — Eckert & Ziegler DE0005659700 Medizintechnik: Bauhaus-Poster mit geometrischen Grundfarben und Atomstruktur-Motiv sowie MEDTECH-Sektor-Schriftzug, Illustration mit AI erstellt.

Eckert & Ziegler stock was trading at EUR 12.46 at Lang & Schwarz on October 5, 2026 at 12:38 p.m. CEST, down 1.11 percent from the prior close of EUR 12.60. The next earnings report is scheduled for November 12, 2026, according to TradingView.

First-half revenue barely moved

In the first half of 2026, Eckert & Ziegler reported revenue of EUR 149.30 million, compared with EUR 148.80 million in the prior-year period. That represents growth of 0.34 percent, leaving the top line effectively flat.

Adjusted EBIT fell from EUR 35.40 million to EUR 33.30 million in the same period, while net income rose 5.00 percent to EUR 22.40 million. These figures show the central tension in the current investment case: radiopharmaceutical demand is supporting profitability, while consolidated revenue growth remains limited.

Guidance stays at EUR 320 million

Trading-Treff reported on September 10, 2026 that management maintained its 2026 outlook for revenue of EUR 320.00 million and adjusted EBIT of EUR 80.00 million after the first-half figures. The implied second-half revenue requirement is EUR 170.70 million, above the EUR 149.30 million generated in the first six months.

The company operates through Medical and Isotope Products and supplies isotope technology for medical, scientific and industrial applications, according to its Eckert & Ziegler investor information. Its 2025 revenue was EUR 312.00 million and adjusted EBIT was EUR 77.70 million, providing a historical benchmark for the 2026 guidance.

November date sets the next test

The November 12 reporting date gives the market a clear checkpoint for the second-half acceleration embedded in the annual outlook. For investors, the key comparison will be whether the company can move from first-half revenue of EUR 149.30 million toward the full-year goal of EUR 320.00 million without a further decline in adjusted EBIT.

Stock trades below prior close

At Lang & Schwarz, the stock was trading at EUR 12.46 on October 5, 2026 at 12:38 p.m. CEST, down 1.11 percent versus the Lang & Schwarz prior close of EUR 12.60 on October 2, 2026. The primary listing is on Xetra.

The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.